Recently, TAT was fused to the Src-inhibiting region of Cx43 (TAT-Cx43266–283), a tumor suppressor protein, exhibiting greater tumor cell selectivity and lower toxicity than dasatinib [236,237]. The gene discussed is SRC; the disease is neoplasm.